Rifaximin in treatment of patients with Irritable bowel syndrome

References (2)

1. Longstreth GF, Thompson WG, Chey WD. Functional bowel disor- ders. Gastroenterology 2006; 130: 1480-91. [CrossRef] Brandt LJ, Chey WD, Foxx-Orenstein AE. An evidence-based posi- tion statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104(Suppl 1): S1-35. [CrossRef] Doshi JA, Cai Q, Buono JL. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. J Manag Care Spec Pharm 2014; 20: 382-90. [CrossRef] Lacy BE, Chey WD, Lembo AJ. New and Emerging Treatment Op- tions for Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) 2015; 11: 1-19.
2. Pimentel M, Park S, Mirocha J. The effect of a nonabsorbed oral anti- biotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145: 557-63. [CrossRef] Sharara AI, Aoun E, Abdul-Baki H. A randomized double-blind place- bo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101: 326-33. [CrossRef] Pimentel M, Lembo A, Chey WD. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32. [CrossRef] Weinstock LB. Long-term outcome of rifaximin therapy in non- constipation irritable bowel syndrome. Dig Dis Sci 2011; 56: 3389-90. [CrossRef] Pimentel M, Morales W, Chua K. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Dig Dis Sci 2011; 56: 2067-72. [CrossRef] Lembo A, Pimentel M, Rao SS. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology 2016; 151: 1113-21. [CrossRef] Zeber-Lubecka N, Kulecka M, Ambrozkiewicz F. Limited pro- longed effects of rifaximin treatment on irritable bowel syn- drome-related differences in the fecal microbiome and metabo- lome. Gut Microbes 2016; 7: 397-413. [CrossRef]